This hypothesis is supported by recent advances in HER2-positive breast cancer treatments with medications such as trastuzumab-emtansine and trastuzumab-deruxtecan – both drug-antibody conjugates – which have demonstrated significant improvements in tumour response rates and survival outcomes [32, 33]. This evidence concerns the gene ERBB2 and neoplasm.